Iterum therapeutics plc (ITRM)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Dec'17
Assets
Current assets:
Cash and cash equivalents

23,257

4,801

28,883

51,241

64,603

44,551

39,598

84,901

8,485

Short-term investments

-

-

0

0

4,997

40,000

68,509

50,370

30,731

Prepaid expenses and other current assets

5,332

6,887

7,956

7,953

7,188

8,390

4,680

6,442

4,957

Current portion of restricted cash

30

30

30

30

30

30

30

-

-

Total current assets

28,619

11,718

36,869

59,224

76,818

92,971

112,817

141,713

44,173

Property and equipment, net

533

572

609

648

675

700

716

735

747

Restricted cash, less current portion

60

60

60

60

90

90

90

120

-

Other assets

13,100

13,401

13,404

11,361

11,551

4,110

3,242

2,902

1,837

Total assets

42,312

25,751

50,942

71,293

89,134

97,871

116,865

145,470

46,757

Liabilities and Shareholders’ Deficit
Current liabilities:
Accounts payable

6,301

15,486

14,527

10,160

6,176

4,041

2,708

8,169

3,152

Accrued expenses

6,244

12,458

17,057

13,956

8,696

7,046

5,323

4,121

3,974

Derivative liability

25,359

-

-

-

-

-

-

-

-

Current portion of long-term debt

5,867

5,800

4,997

3,496

2,056

1,019

-

-

-

Current portion of royalty-linked notes

50

-

-

-

-

-

-

-

-

Income taxes payable

321

200

106

160

248

113

-

-

-

Other current liabilities

2,948

3,042

645

481

442

-

-

-

-

Total current liabilities

47,090

36,986

37,332

28,253

17,618

12,219

8,031

12,290

7,126

Long-term debt, less current portion

18,847

7,625

9,343

10,771

12,139

13,079

-

-

-

Royalty-linked notes, less current portion

10,965

-

-

-

-

-

-

-

-

Long-term debt

-

-

-

-

-

-

14,541

14,505

-

Other liabilities

7,151

7,378

7,363

7,693

7,747

951

195

145

80

Total liabilities

84,053

51,989

54,038

46,717

37,504

26,249

22,767

26,940

7,206

Commitments and contingencies (Note 13)

-

-

-

-

-

-

0

0

-

Shareholders’ deficit:
Ordinary shares, $0.01 par value per share: 50,000,000 shares authorized at March 31, 2020 and December 31, 2019; 14,868,973 shares issued at March 31, 2020 and December 31, 2019

149

149

149

144

144

144

142

142

4

Additional paid-in capital

209,133

208,536

208,037

204,443

203,859

203,271

201,492

201,018

94,227

Accumulated deficit

-251,023

-234,923

-211,282

-180,011

-152,373

-131,793

-107,536

-82,630

-54,737

Total shareholders' deficit

-41,741

-26,238

-3,096

24,576

51,630

71,622

94,098

118,530

39,494

Total liabilities and shareholders’ deficit

42,312

25,751

50,942

71,293

89,134

97,871

116,865

145,470

46,757

Series A Convertible Preferred Shares
Convertible preferred shares

-

-

-

-

-

-

-

-

30

Series B Convertible Preferred Shares
Convertible preferred shares

-

-

-

-

-

-

-

-

27